Conference Program

Nagy Habib ChM, FRCS is a Professor of Surgery and a leading translational researcher in liver cancer and its treatment He pioneered the first clinical trial in the use of adenovirus for the treatment of liver cancer, as well as the use of plasmid gene therapy for hydrodynamic gene delivery He is the first person in the West to publish a clinical trial on the use of adult bone marrow derived stem cells for the treatment of patients with liver insufficiency. Nagy is currently Lead Clinician and Head of the Department of liver Surgery at Imperial College London at the Hammersmith Campus. In June 2007 he was also appointed Pro Rector for Commercial Affairs at the university. He held a gold award from the Advisory Committee for Clinical Excellence, which is given in recognition of exceptional contributions by NHS consultants, and he was named as one of Britain’s top surgeons in December 2011 by the Saturday Times Magazine. In 2015 Nagy was awarded a Foreign Membership of the prestigious French Académie Nationale de Chirurgie.

 i-Cancer Congress- International Cancer Research and Drug Discovery Conference

Nagy A Habib Imperial College London, UK


Brandon Lucke-Wold was born and raised in Colorado Springs, CO. He graduated magna cum laude with a BS in Neuroscience and distinction in honors from Baylor University. He completed his MD/PhD, Master’s in Clinical and Translational Research, and the Global Health Track at West Virginia University School of Medicine. His research focus was on traumatic brain injury, neurosurgical simulation, and stroke. At West Virginia University, he also served as a health coach for the Diabetes Prevention and Management program in Morgantown and Charleston, WV, which significantly improved health outcomes for participants. In addition to his research and public health projects, he is a co-founder of the biotechnology company SwiftScience, the pharmaceutical company ProPhos Neuroscience, and was a science advocate on Capitol Hill through the Washington Fellow’s program. He has also served as president of the WVU chapters for the American Association of Pharmaceutical Scientists, Neurosurgery Interest group, and Erlenmeyer Initiative Entrepreneur group. In addition, he has served as vice president for the graduate student neuroscience interest group, Nu Rho Psi Honor Society, and medical students for global health. He was an active member of the Gold Humanism Honor Society and Alpha Omega Alpha Honor Society. He is currently Vice President of the UF House Staff Council, Chair of the Quality Improvement Committee, on the Board of Directors for the Alachua County Medical Society, and active member of Institutional Review Committee and Accreditation Requirements Review Committee. He is married to Noelle Lucke-Wold and has two children. As a family, they enjoy running with their dogs, rock climbing, and traveling. In his spare time, Brandon frequently runs half marathons and 10ks together with is wife. Brandon also enjoys reading, playing piano, discussing philosophy, and playing chess. He is currently a Pgy6 neurosurgery resident at University of Florida with pursuing endovascular enfolded training and was awarded the Dempsey Cerebrovascular Research Fellowship, SNS Fellowship, Van Wagenen Fellowship, R25 Grant, and SNIS Fellowsh

i-Cancer Congress- International Cancer Research and Drug Discovery Conference -London

Brandon Lucke-Wold University of Florida Health, USA


Professor Charles Coombes, Professor of Medical Oncology, Imperial College London. He is also Hon Consultant Medical Oncologist, Imperial College Healthcare Trust. From October 2010 Professor Coombes is Director of The Imperial CRUK Cancer Centre. He is also Chair of The Imperial Cancer Research (UK) Centre Steering Committee and Theme leader for Cancer, Imperial College London. He is engaged in developing novel methods for prediction of response to endocrine therapy in breast cancer and also carrying out research aimed at understanding the mechanisms of resistance to endocrine therapy and development of novel anti-cancer drugs. In his capacity as Head of Division of Cancer until 30 September 2012, he was responsible for the running of the division, as well as the recruitment and retention of staff. He is personally responsible for running the section of Cancer Cell Biology and has three CRUK Programme Grants and many other project and smaller grants. This department currently has more than 280 scientific staff. The department has doubled in size over the past three years and now has and I4 Professors and twenty sections. His laboratory is focusing on elucidating molecular signals controlling aberrant growth of breast cancer cells with specific focus on the oestrogen receptor and allied cell signalling pathways. He works with scientists engaged in molecular target identification and chemists whose remit is to target specific signalling abnormalities to develop novel therapies for breast cancer. He also runs a translational laboratory which focuses on detection of micrometastatic disease and application to the treatment of breast cancer. He is Chairman of the International Collaborative Cancer Group. This is a multinational trial centre which is based within Imperial College focussing on phase II and phase III studies in breast cancer.

i-Cancer Congress- International Cancer Research and Drug Discovery Conference -London

Charles Coombes Imperial College London, UK


Professor Lu has expertise in the fields of protein chemistry, molecular biology, cancer mechanisms involving p53, the most important tumor suppressor, and c-Myc, one of the important oncoproteins, and translational and pharmacological cancer research. His research has led to the identification of several important protein regulators of p53 and its homologs as well as c-Myc and provides insight into the molecular mechanisms underlying cancer formation. One of his major contributions has been to uncover the previously under-appreciated ribosomal stress-p53 signaling pathway together with two other scientists. Part of his work will be useful for anti-cancer drug development. Recently his lab has identified a novel small molecule called Inauhzin that can suppress tumor growth by activating the p53 pathway as a potential anti-cancer drug candidate. His own and collaborative work has resulted in approximately 130 high-quality publications in scientific journals, such as Nature, Science, Cell, Molecular Cell, Cancer Cell, Nature Communication, EMBO J, PNAS, EMBO Reports, EMBO Molecular Medicine, eLIFE, MCB, JBC, Cancer Research, Cell Death and Differentiation, Oncogene, Developmental Biology, Scientific Reports, and others. He has also served as an editorial board member for the International Journal of Cancer Research (US), the Journal of Biological Chemistry and the International Journal of Biochemistry and Molecular Biology. He has served as a standing member of the Tumor Progression and Metastasis (previous Pathology B) study section at the National Institutes of Health (NIH) and an ad hoc reviewer for a number of NIH study sections, a P01 review panel, and an NCI program review panel. He now serves as a standing member of the Drug Discovery and Molecular Pharmacology (DMP) study section at NIH and as a scientific advisory board member for the Diamond Blackfan Anemia (DBA) Foundation, Inc. in New York. He has been invited more than 200 times to give seminars and lectures at various national and international conferences as well as research institutions and biotech or pharmaceutical companies.

i-Cancer Congress- International Cancer Research and Drug Discovery Conference -London

Hua Lu Tulane University, USA



Alain Chapel, PhD, scientific investigator at IRSN, Laboratory of Radiopathology and Experimental Therapies. For 20 years, he has been developing gene and cell therapy using non-human primates and immune-tolerant mice and rats to protect against the side effects of radiation. He has developed representative experimental models of SAI to investigate the effect of radiation on both radiosensitive hematopoietic cells and their bone marrow microenvironment. He collaborates with clinicians to develop new strategies for treatment of patients after radiation accidents or radiotherapy overexposures. In compassional trials, he has participated in the first establishment of proof of concept of the therapeutic efficacy of mesenchymal stem cells (MSCs) for the treatment of hematopoietic deficit, radiodermatitis and over dosages of radiotherapy. In collaboration with Saint-Antoine Hospital (Paris, France), he has contributed to the first reported correction of deficient hematopoiesis in patients (graft failure and aplastic anemia) thanks to intravenous injection of MSCs restoring the bone marrow microenvironment, mandatory to sustain hematopoiesis after total body irradiation. Currently his work focuses on the development of radio-induced bone marrow aplasia using human hematopoietic stem cells derived from human IPS. He is a member of various learned national and international societies: European Bone Marrow Transplantation Group (EBMT), American Society for Hematology, International Society of Stem Cell Research, Société Francaise de Greffe moelle et de thérapie cellulaire. He is an associate editor of five international journals: World Journal of Stem Cells, World Journal of Gastrointestinal Surgery, World Journal of Radiology, The Open Gene Therapy Journal and Journal of Clinical Rehabilitative Tissue Engineering Research. He has participated in the scientific organization of international conferences

i-Cancer Congress- International Cancer Research and Drug Discovery Conference -London

Alain ChapelIRSN, France


Raffaele Pilla, Pharm.D., Ph.D., Doctor Europaeus, received his Master’s degree in Pharmacy at G. d’Annunzio University in Chieti-Pescara, Italy in 2005, where he also served internships at the Cell Physiology Laboratory and Molecular Biology Laboratory. Prior, he was an Erasmus Student at Faculté de Pharmacie de Reims in Reims, France. He received his Doctor Europaeus in 2010 from Pitié-Salpétrière Institute in Paris, France. Also in 2010, he received his Ph.D. in Biochemistry, Physiology, and Pathology of Muscle at G. d’Annunzio University in Chieti-Pescara, Italy. He was hired as a Postdoctoral Scholar in the Department of Pharmacology and Physiology at the University of South Florida in Tampa, on two research grants funded by the Office of Naval Research (US Navy) and Divers’ Alert Network. He has written and lectured widely worldwide. He has been involved in ongoing research at the University of South Florida with the use of ketone esters.

i-Cancer Congress- International Cancer Research and Drug Discovery Conference -London

Raffaele PillaSt. John of God Hospital, Italy


Dr Olubukola Ayodele is a Consultant Medical Oncologist at the University Hospitals of Leicester NHS Trust, UK who specializes in the management of breast, and genitourinary (including germ cell tumours) malignancies. She is an honorary Senior Lecturer at the University of Leicester and the Head of Breast Cancer Clinical Trials Unit at the Leicester Cancer Research Centre. She obtained a dual fellowship in drug development and sarcoma from the Princess Margaret Cancer Centre (PMCC) in Toronto, Canada, following specialist oncology training in the Republic of Ireland. She is the inaugural recipient of the ISMO-PMCC collaboration fellowship award in 2018. She is a recipient of the 2021 ASCO Conquer Cancer Endowed Merit award for her work in the use of immunotherapy and molecularly targeted agents in the treatment of Leiomyosarcoma. She is the author of multiple publications including a book chapter and serves as a reviewer for several scientific journals. Dr Ayodele has a portfolio of academic and commercial clinical trials in breast and urological malignancies which she runs alongside collaborative translational research projects focusing on molecular drivers and biomarkers in breast cancer. She has received multiple grants for her research work.

i-Cancer Congress- International Cancer Research and Drug Discovery Conference -London

Olubukola AyodeleUniversity Hospitals of Leicester NHS Trust, UK


Professor Michael Lisanti began his education at New York University, graduating Magna Cum Laude in Chemistry. He obtained his MD-PhD degrees at Cornell University Medical College in Cell Biology and Genetics. From 1992-96, he was a Fellow at the Whitehead Institute at MIT. After several distinguished appointments at the Albert Einstein College of Medicine and the Kimmel Centre, he joined the Breakthrough Breast Cancer Research Unit in 2012 as Professor of Cancer Biology, at The University of Manchester, in the United Kingdom (UK). Following his appointment to the Kimmel Cancer Centre in 2006, he was selected for the leadership of the Program in Molecular Biology and Genetics of Cancer. In 2009, he became the Chair of the Department of Stem Cell Biology and Regenerative Medicine at Thomas Jefferson University. He also served as the former Editor-in-Chief of the American Journal of Pathology. In Manchester, he previously held the Muriel Edith Rickman Chair of Breast Oncology.

 Michael Lisanti_Speaker_iWomenHealth

Michael LisantiUniversity of Salford, United Kingdom

10 : 00-10 : 40

Mauro Ferrari is a nanoscientist and leader in the field of nanomedicine. He served as special expert on nanotechnology for the National Cancer Institute (2003-2005) and was instrumental in establishing the Alliance for Nanotechnology in Cancer in 2004. Ferrari has produced more than 350 publications, including seven books and 41 issued patents in the US and Europe. Ferrari's research uses nanotechnology, microtechnology, physical sciences, mathematics, biomechanics, and material sciences to develop new technologies for health care applications like drug delivery and cancer therapeutics. He leads a physical sciences in oncology center, one of a network of centers sponsored by the National Institutes of Health National Cancer Center. The research of this center focuses on understanding the physical and biomechanical biological barriers that reduce the efficacy of cancer therapeutics.He developed a new drug called iNPG-pDox, composed of silicon nanoparticles loaded with polymeric doxorubicin, that had better results at lower doses in animal models compared to standard doxorubicin chemotherapy for metastatic breast cancer.

i-WomenHealth Conference-Mauro Ferrari

Mauro Ferrari University of Washington, USA

10 : 45-11 : 25


11 : 25-11 : 45

Jamal Zekri is a Professor of Medicine at AL-FAISAL University and a Consultant Medical Oncologist, King Faisal Specialist Hospital & Research Centre - Jeddah, Saudi Arabia. Prof. Zekri received his higher medical oncology training in the UK where he was certified and practised as a consultant. He moved to Saudi Arabia and was the head of the medical oncology section for 8 years. He acted as the deputy director of the research centre (Jeddah) for 3 years. He is also an active member of the National Cancer Management Guidelines Task Force for Gastrointestinal and Breast Cancers. He is a member of the Africa and Middle East Uro-oncology group and a co-founder of the Red Sea Lung Cancer Group. Prof. Zekri has published 88 articles in peer-reviewed journals and 2 oncology chapters in a book. He presented about 60 abstracts of original research at several international conferences and he is a peer reviewer in many scientific journals.


Jamal ZekriKing Faisal Specialist Hospital & Research Centre , Saudi Arabia

11 : 45-12 : 15

Abstract: Background: Fertility is a quite important issue for the quality of life of young women with breast cancer (BC). The decision-making process about fertility in these women is complex and might be greatly facilitated through shared decision-making between patients and professionals. Method: A web-based decision aid (DA) was developed from the review of updated scientific evidence. Subsequently, a group of women with a recent diagnosis of BC was invited to review the DA and provide feedback. The participants received an online questionnaire on acceptability and usability, as well as the link to access the web-based DA. Results: Finally, 29 women with BC evaluated the usefulness and acceptability of the DA. The mean age of the participants was 36.48?4.16 years. The DA was rated as useful (55.2%), easy to use (75.9%), visually attractive (48.3%) and entertaining (37.9%). 51.7% of women reported they would use it if they had to make a decision on fertility preservation (FP) treatments. The information contained in the DA was clear (75.9%) and useful for choosing a treatment (51.7%). 62.1% would recommend it, 48% would use it to discuss options with their clinician, and 41.4% reported having learned new things about FP. Conclusion: This DA on FP has been well valued by the participants in different aspects related to acceptability and usability. To improve the potential benefits of DAs, greater efforts are needed to ensure the incorporation of these support resources in the consultations of the professionals in charge of the treatment plans of BC patients.


Alezandra Torres CastanoEvaluation Service of the Canary Islands Health Service (SESCS), Spain

12 : 20-12 : 40

Jennifer Crowell is the Founder and Managing Director of Evulva, an early-stage virtual health literacy platform aiming to address inequalities in vulvovaginal health through innovative education technologies. Health literacy is a strong predictor of health status. Being able to ask the right questions or understand a diagnosis can often be taken for granted. 4/10 adults in the UK are unable to comprehend and/or act on health information; this increases to 6/10 adults when numeracy skills are required for comprehension. Low health literacy is largely unaddressed by public health or in clinical practice. We are aiming to improve health outcomes with personalised adaptive learning that is culturally representative, trans/queer-inclusive, and meets each user at whatever life stage and literacy level they are at. Jennifer’s passion for solving the health literacy crisis in vulvovaginal health began as a Perinatal Neuroscientist. She has 16 years of experience in non-profit and 5 years as a clinical researcher. She studied an MSc in Neuroimaging for Clinical and Cognitive Neuroscience at The University of Manchester having completed two BAs in Developmental Psychology and Globalization/Urban Studies at Portland State University.

i-WomenHealth-Speaker-   Jennifer Crowell

Jennifer Crowell Evulva, UK

12 : 45-13 : 05

Abstract: Background: The main imaging modalities used to assess female infertility are hysterosalpingography (HSG) and transvaginal ultra-sonography. Hysterosalpingography is widely used to assess tubal patency, and can also be used to guide tubal recanalization. The aim of this study was to compare Spontaneous pregnancy rate after hysterosalpingography (HSG) versus saline infusion sonogram done under high pressure (SIStreat) in women suffering from infertility. Materials Methods: A prospective, randomized controlled clinical trial was done in the period from March 2020 till April 2021 on 183 eligible women recruited from infertility outpatient Clinic of El-shatby University hospital, Alexandria, Egypt. Patients were randomized into two main groups; "group A" did HSG and "group B" did conventional SIS. Patient with tubes patent under low pressure were assigned as "group B1" and patients with tubes which are occluded under low pressure were assigned as "group B2" and subjected to SIStreat. The results of tubal patency were observed and recorded in group A and B2, either opened or occluded. All patients were advised to have regular intercourse during the next 6 months of follow up. Pregnancy was diagnosed by serum B-HCG after a missed period and with ultrasonic diagnosis of intact intrauterine gestational sac one week afterwards. Results: out of 93 cases performed HSG (group A), the Number of opened tubes = 79 (84.9%), the Number of occluded tubes = 14 (15.1%) cases and pregnancy rate = 13 (14%) cases. Regarding 71 cases performed SIStreat (group B2), the Number of opened tubes = 62 (87.3%), the Number of occluded tubes = 9 (12.7%) cases and pregnancy rate = 27 (38%) cases. There was no statistical significance difference between the two groups in rate of (opened/ occluded tubes) diagnosis (P = 0.664), but the rate of spontaneous pregnancy after 6 months was statistically significant when compared between both groups (P = <0.001), in favor of the SIStreat group. Conclusion: SIStreat is equal to the conventional HSG in diagnosis of tubal patency. Also, this method increases the rate of post-procedure pregnancy rate more than HSG would do, with the well-known advantages of SIS, such as; no risk of radiation exposure and low cost consumables.


Suzan Samir ElsharkawyAlexandria University, Egypt

13: 10-13 : 30


13 : 30-14 : 30

Susan completed her PhD, in pathology, at University College London Medical School in 1990. She continued with post-doctoral cancer research at the same institution until 1995 when she joined Oxford Brookes University as a Senior Lecturer. She continues in her academic role, teaches undergraduates and heads a small cancer research team. Since 2006 she has had a split role, spending half of her time as the University’s Director of Researcher Development, where she develops, oversees and delivers skills training programmes for research students and research-active staff at all levels across the University. She was promoted to Professor in 2016, partly based on her researcher development work. Susan has been the Vitae representative for the South East region since 2017 and is a Vitae Researcher Developer Senior Fellow.

Susan Brooks_Oxford Brookes University

Susan BrooksOxford Brookes University, Oxford Brookes University

14 : 30-14 : 50

Abstract: Background: Breast cancer is the leading cause of cancer-related death in women worldwide. Although traditional Chinese medicine (TCM) is commonly used by patients with breast cancer, little is known about TCM prescriptions for breast cancer. This study investigated the effects of a new TCM formula, T33, comprising Radix Kansui, Rheum rhabarbarum, Paeonia lactiflora, Jiangbanxia, and Zhigancao on breast cancer cells in vitro and in vivo. Methods: To evaluate the effects of T33 on human breast cancer, HMEpiC, MDA-MB231 and MCF-7 cells were treated with different concentrations of T33 and then analyzed using MTT and Transwell migration assays. To elucidate the involvement of autophagy in the T33-induced death of MDA-MB231 and MCF-7 cells, immunofluorescence staining with LC3-II-specific antibodies was performed. Tumor xenografts were generated by subcutaneously injecting either MDA-MB231 or MCF-7 cells into BALB/c nude mice to determine the effects of T33 on these cell lines in vivo. Results: The experimental results revealed that 0.1 mg/mL, 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33 significantly inhibited the proliferation and invasion of MDA-MB231 and MCF-7 cells. Moreover, significant autophagy was observed in MDA-MB231 and MCF-7 cells in the presence of 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33. An animal study further revealed that both low (200 mg/kg) and high (600 mg/kg) doses of T33 inhibited the proliferation of xenografted breast cancer cells in BALB/c nude mice. Conclusion: These findings demonstrate for the first time that T33 has potential in the treatment of breast cancer owing to its antiproliferative effects and induction of autophagy.

Yu-Te Liu_Speaker_iWomenHealth

Yu-Te LiuChung Shan Medical University, Taiwan

14 : 55-15 : 15

Myra Conway's research focus is on 'Redox Biochemistry, Aging, Neurodegeneration and Biomarker development'. Her research aims to understand how changes in the redox environment can influence the structure/function relationships of proteins under both normal and pathophysiological conditions, in particular proteins with reactive thiol groups. Currently, she is investigating the role of the human branched chain aminotransferase (hBCAT) proteins in glutamate toxicity, a key contributor to the pathogenesis of neurodegenerative disorders such as Alzheimer's disease (AD). She is also developing metabolic maps to ascertain key redox partners that regulate brain glutamate metabolism and protein folding and how this can change with age and age-related conditions. These studies also contribute to the development of biomarker profiles, which are designed to distinguish between patients with Mild Cognitive Impairment (MCI) and AD, a much-needed tool in this research area.

Myra Conway_Speaker_iWomenHealth

Myra ConwayUWE Bristol, United Kingdom

15 : 20-15 : 40

Abstract: Aims To assess fertility outcomes of women treated for cervical cancer within a single cancer unit over a ten-year period. Background Majority of women with cervical cancer are of child-bearing age, hence fertility preservation is a key priority. Loss of fertility is identified as a chief psychological burden of young women who have survived gynaecological cancers leading to stress, depression and sexual dysfunction. Methods We identified patients treated for cervical cancer in our cancer unit over a ten-year period (2009 -2019) (n=313) from the gynae cancer database. Patients included in our study (n=82) were those under 45 years of age at point of treatment and with early-stage cervical cancer. Descriptive statistics was used to assess fertility outcomes. Results In those who received chemoradiotherapy (n=19), median age of the women was 35. Approximately 1/3 of the patient cohort were nulliparous at diagnosis (7, 36.84%). 9/19 were referred for discussion about fertility support prior to chemo-radiotherapy. 8/19 had completed their families prior to the cervical cancer treatment. 1/9 was not referred due to patient choice and no records available for 1/19. The second cohort of patients (n=63) underwent surgical intervention. The median age of patients in this cohort was 34. A large majority (47, 74.60%) had fertility sparing surgeries such as Large Loop Excision of Transformation Zone (LLETZ) and trachelectomy. In the remainder, 14/16 had discussion around fertility prior to surgery while there was no discussion in 2/16. In this cohort, 17/63 had completed their family. 12/63 have had live births recorded following treatment (19.05%). Conclusions This study highlights the incorporation of fertility discussion and referral as part of the care bundle for young women with cervical cancer in alignment with cancer survivorship and improving cancer outcomes.

Sandhya PremNHS, United Kingdom

15 : 45-16 : 00

Abstract: Background Israel’s pronatalist culture results in a social expectation to have children, driving Israel’s high fertility rate of 2.9. Israel’s health policy reflects this expectation through funding unlimited fertility treatment for up to two children. Societal pressure to have children exacerbates challenges of fertility treatment. Furthermore, the lack of financial burden creates a culture of perseverance following treatment failures. The experiences of Israeli women using fertility treatment have been studied. This study aimed to understand the experiences of English-speaking women who migrated to Israel. Methods This was a qualitative study using interviews to investigate the experiences of 13 English-speaking women who migrated to Israel and utilised Israeli state funded fertility treatment. Data were analysed thematically using Framework analysis. Results Three themes were identified: 1. Systemic factors: The lack of financial burden was positive, however, participants struggled to navigate the bureaucratic healthcare system, especially when experiencing a language barrier. 2. Influence of others: Encountering a cold bedside manner coupled with pronatalist cultural expectations was challenging. Participants utilised support from other migrants who appreciated the culture shock. Understanding of healthcare professionals regarding shared religious values improved treatment experiences. 3. Impact: Participants often withdrew socially and described implications upon their lives. Conclusion Navigating a bureaucratic system and pronatalist culture are difficulties experienced by English speaking migrants receiving fertility treatment in Israel, however, lack of financial burden and understanding of religious and cultural beliefs improved treatment experience. Better provision of English resources and further research into supporting women navigating Israel’s pronatalist culture is needed.

Lucy DaviesUniversity of Birmingham, UK

16 : 05-16 : 20

Beatriz Leon Salas is a researcher at the Canary Islands Health Research Foundation (FUNCANIS) linked to the Evaluation Service of the Canary Islands Health Service (SESCS) since 2017. She is an expert in Training Specialists in applied social research and data analysis (CIS). She owns degree in Meta-analysis and systematic reviews: evidence-based decision-making in psychology, medicine and education (UNED) and Expert in Geriatrics and gerontology (ESSSCAN).


Beatriz Leon SalasEvaluation Service of the Canary Islands Health Service (SESCS), Spain


Abstract: Phyllodes tumor of the breast is a rare lesion, accounting for less than 1% of all breast tumors, typically seen in women aged 35 to 55 years. They are classified into benign, borderline or malignant on the basis of histological parameters such as mitotic count, cellular atypia, stromal cellularity and overgrowth, and the nature of tumor borders. However, regardless of their histology, all can recur (Stoffel, et. al. 2018). The objectives of this study are (1) to determine the clinical features of phyllodes tumor associated with its pathologic grade and (2) to formulate a clinical diagnostic criterion to differentiate low grade from high grade phyllodes tumor. This is an IRB-approved analytical cross-sectional single institution study of data of patients diagnosed with phyllodes tumor admitted and treated at a tertiary government medical center from the year 2015-2020. A total of 104 patient data gathered. Six patients were excluded initially because they didn’t undergo definitive surgery. From the 98 patients, 84 were analyzed. Fourteen were excluded upon completion of the gathered data: (4) fibroadenoma; (4) incomplete data for analysis (1) had no specimen submitted; (1) carcinosarcoma, (1) cystosarcoma, (1) acinic cell carcinoma & (3) invasive ductal carcinoma. In this cross-section of patients diagnosed with phyllodes tumor, 69% were benign. Among the clinical factors analyzed, tumor adherence to surrounding tissue was the only factor significantly associated with malignancy. However, it is prudent to manage the tumor like a high-grade tumor at diagnosis to ensure good local control.


Charmagne Loren Yerro-RamosJose R. Reyes Memorial Medical Center, Phillipines


Alezandra Torres Castano is a researcher at the Canary Islands Health Research Foundation (FUNCANIS) linked to the Evaluation Service of the Canary Islands Health Service (SESCS) and a researcher at the Spanish Network of Technology and Performance Assessment Agencies of the National Health System. Health (RedETS). She also has experience and publications in the use of different digital resources to design interventions and resources that improve the health and well-being of citizens.


Alezandra Torres Castano Evaluation Service of the Canary Islands Health Service (SESCS), Spain



16 : 35-16 : 55

Luca Roncati, MD, DMLS, PhD, is the Associate Editor of the European Journal of Gynaecological Oncology (EJGO), Medical Executive at the University Hospital of Modena, and Adjunct Professor at the University of Modena and Reggio Emilia, Italy; he is the author of over 250 scientific publications, he has taken part in the work of various national and international research groups, he has organized several conferences of national relevance, he has attended as a speaker at numerous congresses and seminars, he holds the intellectual property of an Italian and international patent for anticancer therapy, and he has obtained various national and supranational awards.

Luca RoncatiUniversity of Modena and Reggio Emilia, Italy

16 : 55-17 : 05

To be updated soon.

i-WomenHealth Conference-Speaker-Ayse-Kayali-Vatansever

Ayse Kayali VatanseverEge University, Turkey

17 : 10-17 : 25

Mehmet Akif CIFCI is an educator with over ten-year experience. He is an active researcher and has published several research articles, presented at several conferences. Akif is currently working on projects with the Scientific and Technological Research Council of Turkey, and he has provided training sessions on image processing, NLP, food safety, and data analyses. He is also a member of IEEE, CMC, and founder member ABV. His academic interests are AI, ML, DL, Image Processing, Digital Forensic, Food safety, and CPS.


Mehmet Akif CIFCIThe Scientific and Technological Research Council, Turkey

17 : 30-17 : 45

Ling-Qun Hu graduated from Zhejiang University School of Medicine in 1984. He was an Internist in China and a Researcher in Canada. In 2001, after his residency training in USA, he became an Anesthesiologist at Northwestern University Feinberg School of Medicine. He is the Founder and Executive Director of No Pain Labor & Delivery - Global Health Initiative and the Editor-in-Chief of its journal. He has published three books as an author or associate-author and five books as a chief translator or associate-chief translator.

Ling-Qun Hu_Speaker_iWomenHealth

Ling-Qun HuThe Ohio State University Wexner Medical Center, USA

17 : 50-18 : 05

Professor Robert (Rob) Coleman is Emeritus Professor of Medical Oncology in the Department of Oncology and Metabolism at the University of Sheffield. He graduated in medicine from Kings College Hospital Medical School in 1978 and trained in London and Edinburgh before moving to Sheffield in 1991 where he was instrumental in developing clinical cancer research in the city and establishing an internationally respected bone oncology research team in Sheffield. Rob has held many leadership roles within the university and the National Institute for Health Research (NIHR) Cancer Research Network. Despite recently retiring from his formal position at the university, he remains research active and still leads a number of national and international clinical trials. Since 2014 he has been a part-time Medical Director for the global independent medical education provider, prIME Oncology™, developing and delivering both live and on-line educational activities for oncologists and other providers of cancer care. Professor Coleman is a past-president of the Cancer and Bone Society and the founding editor of “Journal of Bone Oncology”. He has published nearly 450 peer reviewed manuscripts and numerous book chapters. He is also a trustee and deputy chair of the board at St Luke’s Hospice in Sheffield and a trustee for the Weston Park Cancer Charity.

R. E. Coleman

R. E. ColemanThe University of Sheffield, United Kingdom


After studying general chemistry and biochemistry at the Albert-Ludwigs-University Freiburg i.Br. (Germany) I got the PhD in biochemistry from the same university. During my PhD work I was trained in virology, cell- and molecular-biology. During several postdoc positions [Department of Molecular Pathology at the University of Bonn (Germany), Charite Berlin (Germany), Department of Gynaecology and Obstetrics at the University of Wuerzburg (Germany)] I received a broad training and knowledge in molecular pathology and cancer research. At the moment I am working in the Department of Molecular Pathology at the ICR (London, UK). I have published more than 60 papers in reputed journals and has been serving as an editorial board member of repute.

Jens Claus Hahne_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Jens Claus HahneThe Institute of Cancer Research, United Kingdom


Dr. Alvaro Macieira-Coelho is a Research Director at the French National Institute of Health. He received an M.D. from the University of Lisbon, Portugal and a Ph.D. from the University of Uppsala, Sweden. He became an intern at the University Hospital in Lisbon and was a research associate at the Wistar Institute in Philadelphia, U.S.A. and at the Department of Cell Biology of the University of Uppsala, Sweden. He became Head of the Department of Cell Pathology at the Cancer Institute in Villejuif, France and was a visiting professor at the University of Linkoping, Sweden. He published 150 papers in professional Journals and nine books on cancer and aging. He received the Fritz Verzar Prize at the University of Vienna, Austria, the Seeds of Science award from the journal CiênciaHoje, and the Career Prize at Lisbon, Portugal, and he is a Dr. Honoris Causa at the University of Linkoping, Sweden and a Johananoff International Visiting Professor at the Mario Negri Institute, Milano, Italy.

Alvaro Macieira-Coelho_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Alvaro Macieira-CoelhoINSERM, France


Adnan Y. Rojeab is a doctor in electrical engineering, and a university lecturer and researcher. His teaching has been with many Universities, like that of the Queen Mary University of London, University of West London. Where he has supplied the students by his own books according to the syllabus of the teaching subject. As well, he is now working at The London College, U.C.K. He is interested in the area of the aspects of the electromagnetic action on the biological system.

Adnan Y. Rojeab_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Adnan Y. RojeabThe London College, United Kingdom


Ming-Shen Dai, MD, Ph.D., is an Associate Professor in School of Medicine, National Defense Medical Center (NDMC) in Taipei, Taiwan, and serves as an Attending Physician and Director at Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital (TSGH). Dr. Dai has extensive experience as clinical research, trial/study initiator and principal Investigator for many clinical trials, with particular interests in breast cancer metastasis, tumor microenvironment, immunotherapy and biomarker. Dr. Dai has many publications in the field of basic and clinical research regarding breast cancer metastasis/treatment appearing in international journals such as Cancer Research, Journal of Medical Sciences, Journal of Immunotherapy and Breast Cancer Research. He is also a peer reviewer in various scientific medical journals, Scientific report, Thoracic cancer, Supportive care in cancer, Theranostics, and Oncologist

Ming-Shen Dai__Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Ming-Shen DaiNational Defense Medical Center, Taiwan


Dr Hadia Moindjie joined Clara Nahmias's laboratory at Gustave Roussy Cancer Research Center (France) in May 2017 as a postdoctoral researcher. Since then, she manages a project entitled “Implication of microtubules associated proteins in chemoresistance of breast and ovarian cancers”. By using multidisciplinary approaches, she worksin the identification of new predictive biomarkers of taxane-based chemotherapy. Before joining Gustave Roussy Cancer Center, she completed her PhD at the Paris Saclay University where she was working on human pregnancy diseases. Dr Moindjie's goal is to combine her two fields of expertises and create her own research laboratory on oncofertility.

Hadia Moindjie__Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Hadia MoindjieINSERM, France


Dr. Rodrigo Orozco is a specialist in Gynecology and Obstetrics. Its field of action is mainly obstetrics focusing on high-risk pregnancy, prenatal diagnosis, and management of malformations and fetal genetic syndromes. He is actively involved in the organization and coordination of training courses for medical specialists in the Spanish Society of Gynecology and Obstetrics (SEGO) At the hospital level, he is the Chief of Obstetrics and the Obstetric Block of the University Hospital Fundación Jiménez Díaz, as well as a collaborating Professor of medicine at the Autonomous University of Madrid and the Alfonso X University of Madrid. He is a principal investigator and collaborator in several multicentre studies in relation to obstetric care and diseases related to placental insufficiency, mainly preeclampsia. His passion is quality in excellence in the treatment of pregnant women, respect for humanized childbirth and the satisfaction of women throughout the gestational process. He also collaborates regularly with television programs as well as with newspapers and magazines to disseminate health information to the population

Rodrigo Orozco Fernández_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Rodrigo Orozco FernándezFundacion Jimenez Diaz, Spain


Dr Jonas received her Ph.D. in female reproductive endocrinology from University College London and conducted postdoctoral research in the field of gonadotrophin hormone biology, where she pioneered the technical development of the technique photoactivated dye, localization microscopy (PD-PALM) for the visualization of individual cell surface GPCR receptors to <10nm resolution. She is currently a lecturer in the Department of Women and Children’s Health, at King’s College London.

Kim Jonas_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Kim JonasKing's College London, United Kingdom


Dr Joo Teoh is a specialist obstetrician & gynaecologist in Perth, Australia. He has completed his subspecialist training in reproductive medicine in Scotland and holds a Doctor of Medicine degree from the University of Glasgow for his research in reproductive immunology. He was also the ex-chairperson of the UK Subspecialist Trainees in Reproductive Medicine before relocating to Australia.

Joo P. Teoh_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Joo P. TeohSpecialist Obstetrician & gynaecologist, Australia


Amani is a senior clinical research specialist with extensive experience in clinical research and medical writing. She earned her Master's degree in Public Health/Epidemiology from the Jordan University of Science and Technology in 2007. She is a speaker for many educational workshops and outreach educational programs.

Amani K. Abu Shaheen_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Amani K. Abu ShaheenKing Fahad Medical City, Saudi Arabia


Dr. Roopa Verghese, is a senior consultant obstetrician and gynecologist by profession who went on to do her Masters in Bioethics from Trinity International University, Chicago. After working for 14 years in all over northern India in remote locations under the aegis of Emmanuel Hospital Association she has now shifted to Muthoot Healthcare in rural Kerala as a full time obstetrician and gynecologist. She also has an added responsibility of being the Deputy Medical Superintendent of the Hospital. Being among the first few trained and qualified bioethicist in India she contributes to the pioneering work for the Center for Bioethics as a part time consultant. Presently she as a faculty of TCB along with CMC, Vellore are engaged in setting up the curriculum for the first every post graduate course in bioethics in India. She strives to practice bio ethically relevant obstetrician and gynecology in rural India given the socioeconomically and cultural difference between the countries of her educational and origin. She is a keen activist representing women’s rights on a much wider platform.

Roopa Verghese_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Roopa VergheseThe Centre of Bioethics, India

16:05- 16:25

Dr. Simon Fishel is Managing Director of the CARE Fertility Group. He is recognized for his pioneering work in IVF (link to ‘CARE Firsts’ on CARE Fertility website), especially in the fields of microinjection for male infertility and preservation of fertility in children with cancer and in developing chromosome screening in IVF using array CGH technology. He has been active in the field for over 30 years, researching at Cambridge with Professor Robert Edwards before the birth of the first IVF baby. He was part of the ‘original team of four’, with Patrick Steptoe, Bob Edwards and John Webster at the world first IVF clinic established in 1980. He has written over 200 scientific articles and edited three books on the subject. Dr. Fishel was awarded a Personal Professorial Chair in Human Reproduction at the University of Nottingham in recognition of his work. In 2009 Simon was honored by Liverpool John Moores University with their highest award of ‘University Fellow’ for “outstanding contribution to science and to humanity”

Simon Fishel_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Simon FishelCarefertility, United Kingdom


Mr Y. Afifi has over 25 years of experience in specialised laparoscopic and reproductive surgeries. He has his PhD from the University of Birmingham and obtained extensive specialised training in minimal invasive surgery. He is the director of the Birmingham Endometriosis Centre and lead consultant of the reproductive surgery unit in Birmingham Women’s Hospital. He receives regional and national referral of patients needs a specialised laparoscopic surgery for management of complex endometriosis, infertility, fibroid, recurrent miscarriage and ovarian problems. He introduced ovarian tissue autografting for patients who opt for surgeries to remove their ovaries. The ovarian graft reversed the menopausal state without artificial hormone replacement. The technique was proven to be very successful with excellent patient satisfaction and led the way for the establishment of ovarian tissue freezing. He is the chair of advanced training in the West Midland School and one of a handful of approved national trainers for advanced laparoscopic surgery. He invented a new surgical technique for safe and successful management of corneal ectopic pregnancy. He has also developed a technique of laparoscopic entry to eliminate the associated risk of injury. He is the author of 6 chapters and over 20 publications. He has been an invited speaker of over 50 international and national conferences. He is the director of 8 international courses for hand on training of different surgical skills.

Yousri Afifi_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Yousri AfifiCarefertility, United Kingdom


Joyce Harper is Professor of Reproductive Science at University College London in the Institute for Women’s Health where she is head of the Reproductive Health Department, Principal Investigator of the Reproductive Science Group, Director of Education and Director of the Centre for Reproductive Health. She is a Director of the Embryology and PGD Academy which she established with Alpesh Doshi in 2014 and founder of Global Women Connected. She is currently studying the social, legal and ethical aspects of assisted reproductive technologies, from social egg freezing to genome editing.

Joyce Harper_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Joyce Harper UCL Institute for Women’s Health, United Kingdom


Chang-Hoon Lee is a professor of Dept. of Korean Medicine Obstetrics and Gynecology, Kyung Hee University, Seoul, South Korea. He graduated from College of Korean Medicine, Kyung Hee University in 1989 and worked as a Korean Medicine Doctor at the military hospital for 3 years. He received training at Kyung Hee University Hospital from 1992 to 1995. In 2005, he received a Ph.D. in Dept. of Clinical Korean Medicine, Graduate School Kyung Hee University. He was appointed Professor at College of Korean Medicine at Kyung Hee University in 2015.

Chang Hoon Lee_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Chang Hoon Lee, Jun Geol Yoon, Hae Ri JiKyung Hee University, Republic of Korea


Abstract: Aim: To identify opportunities for ovarian salvage in children undergoing surgery for OL. Method: Retrospective review of patient records for all children undergoing surgery for OL at a tertiary pediatric surgery unit from 2010-2018. Data were collected on clinical presentation, surgical procedure, gynecology involvement, and histopathology. Data are presented as median (range). Binomial logistic regression was used to identify factors associated with ovary-sparing surgery (OSS). Results: 25 girls were identified (age 11 (0–15) years); 16/25 (64%) were emergency cases, 17/25 (68%) were benign teratoma, 7/25 (28%) were simple cysts, 1 had no histology. The local gynecology team was involved in 9/25 (36%) cases. Regression modeling indicated that emergency surgery and histology were not associated with OSS; however, gynecology involvement was significantly associated (OR 28.7 (1.95-420.5), p=0.014). Conclusion: Children with OL are more likely to undergo OSS when gynecology are involved in their management rather than surgeons alone. To maximize the opportunity for ovarian salvage, we recommend that surgeons managing children with OL do so in coordination with the local gynecology team.

Dipak Karavadara_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Dipak KaravadaraKings College London, United Kingdom


Aims: To evaluate compliance of SCCG guidelines to treatments available before hysterectomy.(1,2) Method: a Retrospective cohort study (January 2016 to December 2018) identified all women with benign hysterectomies. Electronic notes, correspondence letters and investigation results were retrieved to collect information on the management of HMB. Results: 131 of the 459 women identified had a hysterectomy for HMB. In 84.7-98.5% of women, treatments were considered (i.e. offered/tried, contraindicated, attempted or patient declined). Undocumented data ranged from 1.5-15.3% across all treatments. 36.6% of women declined Depo-Provera® for concerns over weight gain and irregular bleeding. Conclusions: Hysterectomies in women <40 years were after the failure of all treatments before hysterectomy. Overall, all treatments were well considered as per SCCG recommendations, however, a high proportion particularly Depo-Provera® was declined. I recommend a proforma for treatment options, acting as an aide memoir for clinicians, improving documentation and helping with future audits.

Rabiat Umar_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Rabiat UmarNewcastle University, United Kingdom


Aim: This study, in order to determine the effect of chewing and fennel tea on intestinal motility after cesarean section. Materials and Methods: This study was carried out at a postpartum clinic of a university hospital in Istanbul. Using SPSS (Statistical Package for Social Sciences) program, number, mean and percentage calculations, Student's T-test for paired comparisons, One-way analysis of variance in triple comparisons, Correlation and Tukey HSD test was used. Results: In the third group all of the implementations done, gut sounds were heard earlier than other groups and control group, flatus and excretion have come out earlier (p<0,05). Conclusion: Its thought that this study is going to lead the other studies which will ve applied on different patient groups that have more samplings. Because gum chewing and fennel tea increase the intestinal motility after caserean birth, in terms of shortening effect on discharge span and preventing postoperative ileus, they were suggested to implement all together in postoperative routine care.

Ruveyda Olmez_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Ruveyda Olmez Marmara University, Turkey


Anita Grigoriadis is a Senior Lecturer in the School of Cancer and Pharmaceutical Sciences at King’s College London (KCL), the School Lead (International) and Training Lead for the CRUK KHP Centre, and holds a guest lecturership at Birkbeck College, University of London. Anita started her scientific career at the Research Institute of Molecular Pathology (IMP), University of Vienna (Austria), pursuing a joint Ph.D. between the Ludwig Institute for Cancer Research (LICR), London, and Faculty of Natural Sciences, Salzburg (Austria). Her postdoctoral training on breast cancer genomics started at the LICR, and continued with Professor Alan Ashworth at the Breakthrough Breast Cancer Centre (London), before joining Professor Andrew Tutt at the Breast Cancer NOW Unit at KCL. Since 2013 Anita leads the KCL Cancer Bioinformatics group, which implements analytical approaches to exploit large complex data sets derived from clinically annotated samples and model systems. Her work focuses on the identification of molecular patterns pathognomonic for DNA damage repair defects, plus their immune microenvironment correlates, mainly in triple negative breast cancers, but also pan-cancer. In parallel, Anita leads the newly formed initiative of “CAncer microBiome ImmuNology Data science” (CABINDA) at KCL, which investigates histomorphological features reflective of local and systemic immune responses, a patient’s resident microbial communities and how the sum of these individual components influence treatment response and disease progression.

Anita Grigoriadis_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Anita GrigoriadisKing’s College London, United Kingdom


Dr Shamley is Director of the Clinical Research Centre at UCT and has a track record of postgraduate student supervision to PhD level, publications and grant success. Key positions include: Head of Physiotherapy at OBU, Deputy Director for Research at OBU, and Deputy Director, Bournemouth CTU. External consultancies include peer reviewing for journals, grant reviewing for the HTA (UK), NRF (SA), Flanders Foundation (Belgium) and EDCTP (EU). As part of her movement towards management in health sciences, she has recently completed an Executive MBA. Her research programme includes proteomics and genomics of latent effects of adjuvant therapy in breast cancer survivors. Dr Shamley is also committed to the development of care pathways for post cancer treatment morbidity, which will provide evidence for the Cancer Survivorship Plan for SA. Her program of research aims to identify those patients at risk and target the treatment programmes accordingly. The REACH program of research intends to contribute to this end and has two main goals:1. To identify risk factors for the development of upper limb morbidity in breast cancer survivors and 2. To develop integrated care pathways for managing Lymphoedema and upper limb pain and disability. She has developed an Early Warning System (EWS) to identify patients at risk of developing complications in response to treatment. The current EWS is based on clinical risk factors and is being used in the UK and Australia. In addition, she has a team exploring potential systemic causes of morbidity by correlating the clinical phenotype of the shoulder after treatment for breast cancer with biomarkers of inflammation and angiogenesis, and their associated genetic variants. Dr Shamley is leading on the Cancer Survivorship Plan for SA. In addition to her research work she is a founding member of the African Clinical Trials Consortium and plays an active role in developing research capacity in collaboration with many other NGO’s.

Delva Shamley_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Delva ShamleyUniversity of Cape Town, South Africa


Miss Salma Naseem: MBBS, FRCS, FEBS, MSc (Breast Evaluation, London), PgDip (OPBS, UK) I work as a Consultant Oncoplastic Breast Surgeon in the UK. As an experienced breast clinician, I enjoy teaching and imparting my knowledge and expertise to others both in the formal and informal settings. Since graduating and obtaining my initial surgical training from Pakistan, I have maintained my links with the teaching hospitals in Karachi. This has created opportunities for me to deliver talks on breast conditions and undertake clinical and operating sessions in the teaching hospitals. Most notably, I am a tutor and an examiner of Intercollegiate MRCS for the Royal College of Surgeons, England, both nationally and Internationally. On a local level, I have extended my expertise in guiding the sixth form students in the preparation for medical university interviews. My enthusiasm in this area led me to publish an article about this subject. Furthermore, in 2015/16, I collaborated with the consultant surgical oncologist at Maadi Military Hospital to help them in the setting up and running of Breast Services in a Military hospital in Cairo, Egypt, based on the UK model with advice to protocol and guidelines. I continued to be engaged in advising on the follow-up pathways for breast cancer patients.

Salma Naseem_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Salma NaseemYeovil District Hospital, United Kingdom


Fiona is a University Research Lecturer at the Kennedy Institute of Rheumatology, NDORMS at the University of Oxford and was appointed as an honorary consultant rheumatologist at the Nuffield Orthopaedic Centre, Oxford in 2013. She leads the Clinical Translation theme within the Arthritis Research UK Centre for Osteoarthritis Pathogenesis. She has a PhD in cartilage biochemistry from Imperial College London, and completed specialist training in rheumatology in West London. She has first class honours degrees for both B.Med.Sci and MBBS from University of Newcastle-Upon Tyne. Her research interest is in the diagnosis, stratification and treatment of osteoarthritis. Fiona sits on a number of steering committees which focus on the treatment of this condition: the James Lind Alliance for Early Osteoarthritis; ACHE (an assessment tool for arthroplasty); HIT (clinical trial in OA, University of Keele). She is Musculoskeletal Disorders Research Advisory Group lead for Arthritis Research UK, and also a clinical spokeswoman for the charity. Fiona won an OARSI Young Investigator award in 2014 and the British Society for Rheumatology's Michael Mason Prize in 2016 for her work on biomarkers of joint injury.

Fionaa watt_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Fiona WattThe Kennedy Institute of Rheumatology, University of Oxford, United Kingdom


Dr. Kyono graduated from Fukushima Medical College, receiving his MD in 1978 and his PhD in 1984 from in Obstetrics and Gynecology (reproductive biology) in Tohoku University. He was a member of the Tohoku University team that succeeded in producing the first IVF pregnancy and delivery in Japan in 1983. He also succeeded in the first birth following frozen-thawed oocytes by slow freezing in Japan in 2001 and after using vitrified-warmed oocytes in an acute lymphoblastic leukemia patient in 2012. He made a medical clinic with reproductive medicine in Furukawa city in 1995. He has been a President of Kyono ART Clinic in Sendai since 2007, Kyono ART Clinic Takanawa in Tokyo since 2012, and Human OvarianTissue Preservation Enterprise (HOPE) in Tokyo since 2016. He became a visiting professor at Toho University in Tokyo. Dr. Kyono’s long-term research interests include studies on cryopreservation (oocyte, embryo, and ovarian tissue) for fertility preservation, in-vitro maturation for PCOS, preimplantation genetic testing, endometrial receptive array, andrology, and reproductive endocrinology.

Koichi Kyono_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Koichi KyonoKyono ART Clinic, Japan


Abstract: Maternal-fetal medicine specialists should have a key role in the early diagnosis and prevention of many non-communicable diseases by implementing a framework for patient consultation and interdisciplinary networks. Progress will depend on our ability to successfully increase health literacy of women, to inform health care politicians about early interventions instead of wasting resources for increasing numbers of chronic diseases and finally to improve the communication to health care specialists following women and children after birth.

Birgit Arabin_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Birgit ArabinClara Angela Foundation, Germany

14:45- 15:05

Dr. Shazia Iqbal is working as Assistant Professor Obstetrics and Gynecology & Director of Medical Education at AlFarabi College of Medicine, Riyadh, Saudi Arabia. She is the course Director for Obstetrics & Gynaecology and communication skills. She is fellow of the College of Physicians and Surgeons Pakistan (CPSP), Associate Member of RCOG. She is masters in medical education from the University of Liverpool, UK. Her primary goal is to deliver the highest possible standards of education to undergraduate MBBS students and postgraduate trainees. She is keenly involved in faculty development and review of curriculum at medical institutions with a special interest in communications skills enhancement and promoting the pedagogical techniques by using educational technologies.

Shazia Iqbal_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Shazia Iqbal AlFarabi College of Medicine, Riyadh

15:10- 15:30

Abstract: Objective: To obtain proper predictive values of uterine artery doppler combined with extreme maternal age (EMA) in prediction of severe preeclampsia (SPE) and Intrauterine fetal growth restriction (IUGR). Methods: Observational retrospective study and diagnostic prediction model designed at Instituto Nacional Materno Perinatal (INMP) in Peru with participation of 6697 pregnant women between 11 and 40 weeks of gestational age (2009-2016). Reference curves of the percentile uterine artery pulsatility index for each gestational age were constructed using the Royston and Wright exponential distribution method. Logistic regression was used for the multivariate analysis, the ROC curve was performed and the AUC was calculated with the respective 95% CI for each variable separately and combined; were estimated with a p<0.05. Regression coefficients for each variable were obtained with p<0.01 and the odds ratios adjusted with a 95% CI. Results: The AUC for predicting SPE were 0.65 for UP95, 0.60 for EMA and 0.72 for UP95 and EMA combine. For predicting IUGR were 0.65, 0.54 and 0.68 respectively. The sensitivity for SPE with a 10% of false positives were 42% for UP95, 22% for EMA, and 43% for EMA plus UP95 combined. The sensitivity for IUGR with the same false positive rate was 45% for UP95, 10% for EMA, and 45% when using both variables. The adjusted risk of each variable for SPE was UP95 OR=6.1 (95% CI 4.2-9.1) and for EMA OR=3.2 (95% CI 2.3–4.6); for IUGR was respectively 6.2 (95% CI 4.4-8.8) and 2.0 (95% CI 1.4–2.9). Conclusions Certainty diagnostic is better using UP95 and EMA than applying each variable individually in the prediction of SPE and IUGR. Key words: severe preeclampsia, intrauterine growth restriction, pulsatility index of uterine arteries, maternal age, predictive value.

Elizabeth Ramos Orosco_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Elizabeth Ramos OroscoUniversidad Peruana de Ciencias Aplicadas, Peru


Abstract: Embryo implantation is essential for a successful pregnancy, and an elaborate synchronization between the receptive endometrium and trophoblast is required to achieve this implantation. To increase ‘endometrial receptivity’, the endometrium undergoes transformation processes including responses of adhesion molecules and cellular and molecular cell to cell communication. Many natural substances from traditional herbs have been studied to aid in the achievement of successful implantation, and in this study, decursinol, a major compound extracted from the traditional Korean herbal medicine, Angelica gigas Nakai, was selected as the candidate for analysis. Although A. gigas has been traditionally used to promote healthy pregnancy, whether it has positive effects on embryonic implantation has not been validated. The objective of this study was to demonstrate the contribution of decursinol to the enhancement of endometrial receptivity using the human endometrial implantation medel, Ishikawa cells, and JAr cell spheroids. Decursinol significantly (P < 0.05) increased the expression of important endometrial adhesion molecules such as integrin ?1, ?3, ?5 and L-selectin mRNAs and integrin ?5 and L-selectin in protein, when studied with qRT-PCR and Western blotting. The adhesion rate of JAr spheroids to decursinol treated-Ishikawa cells also increased significantly. Furthermore, decursinol induced an increase in the release of exosomes from Ishikawa cells and decursinol-induced exosomes showed autocrine (to Ishikawa cells) and paracrine (to JAr cells) positive effects on our implantation model. These findings propose that decursinol could serve as a new and alternative solution for patients who are infertile.

Seong-Eun Kim _Joo Eun Lee_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Seong-Eun Kim and Joo Eun LeeKonyang University, South Korea


The author received an honorable Ph.D. in mathematics and majored in engineering at MIT. He attended different universities over 17 years and studied seven academic disciplines. He has spent 20,000 hours in T2D research. First, he studied six metabolic diseases and food nutrition from 2010 to 2013, then conducted his own diabetes research from 2014 to 2018. His approach is “quantitative medicine” based on mathematics, physics, optical and electronics physics, engineering modeling, signal processing, computer science, big data analytics, statistics, machine learning, and artificial intelligence. His main focus is on preventive medicine using prediction tools. He believes that the better the prediction, the more control you have

Gerald C. Hsu_Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Gerald C. HsueclaireMD Founda?on, USA


Özlem Gün Eryilmaz has graduated from Hacettepe University Faculty of Medicine in 1997 and completed her Ph.D. at the age of 26 from Government Hospital of Women’s Health Education and Research Hospital. After 22 years of work and research in government, she works now in Ortadogu Private Hospital in Ankara. For the last 9 years, she is interested in Infertility, Reproductive Medicine, IVF, and Endometriosis. She has over 25 publications that have been cited over 200 times. Related to endometriosis, she had visited the Reproductive Medicine Department of University Collage of London in 2015 and have international certificates.

Ozlem Gun Eryilmaz _Speaker_ International Women Health and Breast Cancer Conference_ iWomen Health 2019

Ozlem Gun Eryilmaz Ortadogu Hospitals, Turkey

16:20- 16:40

Gabrielle Harrison completed a Masters degree in 2014 in International Relations, she then worked for various non-governmental organisations and charities including the following issues: HIV/AIDS, environmental issues, women’s education in the developing world and raising awareness of female genital mutilation. She has since returned to education and is studying Medicine, graduating in 2020. Gabrielle’s research interests are broad from FGM, women’s health and refugee health to current patterns in blunt and penetrating trauma. She works locally with vulnerable populations including the homeless and sex workers.

Gabrielle Harrison_Speaker _iWomenHealth_International Women Health and Breast Cancer Conference

Gabrielle HarrisonThe University of Warwick, United Kingdom

16:30- 16:45

Miss Jun Yu Chen is a fourth-year medical student at the University of Glasgow, Scotland. Jun recently received BSc First Class with Honours Medical Sciences after completing her intercalated degree in Clinical Medicine (Medical Sciences) specialising in cardiovascular medicine. Jun has been active in research throughout medical school in a wide range of specialities including palliative care, nutrition, respiratory medicine and hypertension. Jun has been active in many medical societies and is currently the president of the Glasgow Anaesthetics Society which holds regular revision events, clinical skills practice and an annual conference attended by students from across the UK. Jun is currently undertaking a summer studentship at the Institute of Cardiovascular and Medical Sciences in Glasgow, funded by the British Heart Foundation and the Carnegie Trust looking into sodium accumulation in hypertension in animal models and human subjects.

Jun Yu Chen_YRF_iWomenHealth COnference_International Women Health and Breat Cancer Conference

Jun Yu ChenUniversity of Glasgow, United Kingdom

16 : 45-17 : 00